Cargando…
Real-world effectiveness of azvudine for patients infected with the SARS-CoV-2 omicron subvariant BA.5 in an intensive care unit
BACKGROUND: Azvudine (FNC) has been shown to be effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but data regarding the Omicron BA.5.1.3 subvariant are lacking. This retrospective analysis investigated the effectiveness and safety of FNC against the SARS-CoV-2 Omicron...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10586978/ https://www.ncbi.nlm.nih.gov/pubmed/37868850 http://dx.doi.org/10.21037/jtd-23-1093 |
_version_ | 1785123258165624832 |
---|---|
author | Qi, Xiuping Yang, Yun Gong, Baoqiang Li, Zhiwei Liang, Dong |
author_facet | Qi, Xiuping Yang, Yun Gong, Baoqiang Li, Zhiwei Liang, Dong |
author_sort | Qi, Xiuping |
collection | PubMed |
description | BACKGROUND: Azvudine (FNC) has been shown to be effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but data regarding the Omicron BA.5.1.3 subvariant are lacking. This retrospective analysis investigated the effectiveness and safety of FNC against the SARS-CoV-2 Omicron BA.5.1.3 subvariant in a real-world setting, utilizing data from a patient cohort at our institution. METHODS: Data were retrospectively collected from patients admitted to the intensive care unit (ICU) of Sanya Central Hospital during the Sanya outbreak (August 13 to September 7, 2022). The patients, all infected with the Omicron BA.5.1.3 subvariant, were selected based on predefined inclusion and exclusion criteria. The patients were classified as the FNC (azvudine 5 mg, qd + standard supportive treatment) and non-FNC (standard supportive treatment only) groups. RESULTS: The study comprised 13 patients, with 6 and 7 in the FNC and non-FNC groups, respectively. Baseline data, clinical features, and imaging manifestations were generally similar between the two groups. However, patients administered FNC demonstrated significantly lower levels of inflammatory indicators at baseline. Although there was no significant difference in the duration of ICU stay between the FNC and non-FNC groups, overall ICU stay appeared to be reduced in the FNC group. CONCLUSIONS: FNC emerges as a feasible treatment against the Omicron BA.5.1.3 subvariant. It may reduce ICU stay and demonstrate a promising safety profile without major side effects or disruption to normal physiological parameters. |
format | Online Article Text |
id | pubmed-10586978 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-105869782023-10-21 Real-world effectiveness of azvudine for patients infected with the SARS-CoV-2 omicron subvariant BA.5 in an intensive care unit Qi, Xiuping Yang, Yun Gong, Baoqiang Li, Zhiwei Liang, Dong J Thorac Dis Original Article BACKGROUND: Azvudine (FNC) has been shown to be effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but data regarding the Omicron BA.5.1.3 subvariant are lacking. This retrospective analysis investigated the effectiveness and safety of FNC against the SARS-CoV-2 Omicron BA.5.1.3 subvariant in a real-world setting, utilizing data from a patient cohort at our institution. METHODS: Data were retrospectively collected from patients admitted to the intensive care unit (ICU) of Sanya Central Hospital during the Sanya outbreak (August 13 to September 7, 2022). The patients, all infected with the Omicron BA.5.1.3 subvariant, were selected based on predefined inclusion and exclusion criteria. The patients were classified as the FNC (azvudine 5 mg, qd + standard supportive treatment) and non-FNC (standard supportive treatment only) groups. RESULTS: The study comprised 13 patients, with 6 and 7 in the FNC and non-FNC groups, respectively. Baseline data, clinical features, and imaging manifestations were generally similar between the two groups. However, patients administered FNC demonstrated significantly lower levels of inflammatory indicators at baseline. Although there was no significant difference in the duration of ICU stay between the FNC and non-FNC groups, overall ICU stay appeared to be reduced in the FNC group. CONCLUSIONS: FNC emerges as a feasible treatment against the Omicron BA.5.1.3 subvariant. It may reduce ICU stay and demonstrate a promising safety profile without major side effects or disruption to normal physiological parameters. AME Publishing Company 2023-09-25 2023-09-28 /pmc/articles/PMC10586978/ /pubmed/37868850 http://dx.doi.org/10.21037/jtd-23-1093 Text en 2023 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Qi, Xiuping Yang, Yun Gong, Baoqiang Li, Zhiwei Liang, Dong Real-world effectiveness of azvudine for patients infected with the SARS-CoV-2 omicron subvariant BA.5 in an intensive care unit |
title | Real-world effectiveness of azvudine for patients infected with the SARS-CoV-2 omicron subvariant BA.5 in an intensive care unit |
title_full | Real-world effectiveness of azvudine for patients infected with the SARS-CoV-2 omicron subvariant BA.5 in an intensive care unit |
title_fullStr | Real-world effectiveness of azvudine for patients infected with the SARS-CoV-2 omicron subvariant BA.5 in an intensive care unit |
title_full_unstemmed | Real-world effectiveness of azvudine for patients infected with the SARS-CoV-2 omicron subvariant BA.5 in an intensive care unit |
title_short | Real-world effectiveness of azvudine for patients infected with the SARS-CoV-2 omicron subvariant BA.5 in an intensive care unit |
title_sort | real-world effectiveness of azvudine for patients infected with the sars-cov-2 omicron subvariant ba.5 in an intensive care unit |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10586978/ https://www.ncbi.nlm.nih.gov/pubmed/37868850 http://dx.doi.org/10.21037/jtd-23-1093 |
work_keys_str_mv | AT qixiuping realworldeffectivenessofazvudineforpatientsinfectedwiththesarscov2omicronsubvariantba5inanintensivecareunit AT yangyun realworldeffectivenessofazvudineforpatientsinfectedwiththesarscov2omicronsubvariantba5inanintensivecareunit AT gongbaoqiang realworldeffectivenessofazvudineforpatientsinfectedwiththesarscov2omicronsubvariantba5inanintensivecareunit AT lizhiwei realworldeffectivenessofazvudineforpatientsinfectedwiththesarscov2omicronsubvariantba5inanintensivecareunit AT liangdong realworldeffectivenessofazvudineforpatientsinfectedwiththesarscov2omicronsubvariantba5inanintensivecareunit |